PALI

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027 IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026 Strong balance sheet expected to support execution through key Phase 2 clinical readouts Denver, CO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. During the quarter, the Company completed key regulatory and operational activities supporting the planned commencement of the Phase 2 ASCENTRA-UC trial of PALI-2108 in the second half of 2026. Palisade Bio is advancing PALI-2108 into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD), supported by encouraging results from its completed Phase 1 clinical trial. Key Takeaways from the Phase 1 Clinical Trial Across the Phase 1 clinical trial, PALI-2108 demonstrated favorable safety and tolerability, sustained exposure of the active metabolite above the IC90 threshold, targeted distribution in the ileum and colon, and pharmacodynamic (PD) activity across key inflammatory and fibrotic pathways. The Phase 1 clinical trial included five patients with UC and five patients with fibrostenotic Crohn’s disease (FSCD). In the UC cohort, 5 out of 5 patients achieved clinical response and 2 out of 5 achieved clinical remission based on Modified Mayo Score. In the FSCD cohort, PALI-2108 reduced mean SES-CD score by approximately 47.5% (a 3.8-point improvement), with 2 out of 5 patients achieving both endoscopic response and remission based on SES-CD. Together, these findings provide a strong foundation for the planned commencement of the Phase 2 ASCENTRA-UC trial in the second half of 2026. The Company also intends to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Phase 2 ASCENTRA-CD trial of PALI-2108 in the second half of 2026. “The second quarter marked a decisive transition for Palisade Bio as we completed the regulatory and operational work required to advance PALI-2108 into Phase 2 development,” said JD Finley, Chief Executive Officer of Palisade Bio. “With FDA clearance of our IND, encouraging Phase 1 results and a strong financial position, we expect to commence the Phase 2 ASCENTRA-UC trial in the second half of 2026. PALI-2108 was engineered for targeted activation within the gastrointestinal tract, with the goal of delivering sustained PDE4 inhibition while improving tolerability and convenience. We believe the ASCENTRA-UC Phase 2 trial represents a significant opportunity to demonstrate that differentiated profile in a larger patient population and establish PALI-2108 as a potentially best-in-class, once-daily oral therapy for IBD.” Recent Highlights Strengthened the Board of Directors with the appointments of biopharmaceutical industry veterans Robert Baltera and Jordan Zwick, adding expertise across biotechnology leadership, strategic transactions and capital markets as the Company advances PALI-2108 into Phase 2 development. Scientific Presentations Presented Phase 1 translational findings for PALI-2108 at Digestive Disease Week (DDW) 2026, highlighting rapid clinical, histologic and biomarker improvements. Showcased PALI-2108’s targeted PDE4 inhibition strategy in fibrostenotic Crohn’s disease at the 4th Annual Precision Medicine in IBD Summit. Discussed the role of intestinal fibrosis and PALI-2108’s therapeutic potential at a New York Academy of Sciences symposium. Additional PALI-2108 data to be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and United European Gastroenterology (UEG) Week 2026. Advancing PALI-2108 Into Phase 2 Development Phase 2 ASCENTRA-UC Received FDA clearance of the IND application for PALI-2108 Phase 2 UC clinical trial expected to commence in 2H 2026 Primary efficacy readout expected 2H 2027 Phase 2 ASCENTRA-CD IND submission for the Phase 2 CD trial expected 2H 2026 Phase 2 CD clinical trial commencement targeted for 1Q 2027 Primary efficacy readout expected in early 2028 Mitch Jones, M.D., Ph.D., President and Chief Medical Officer of Palisade Bio, added, “Crohn’s disease is a core component of the PALI-2108 clinical development program and is advancing in parallel with ASCENTRA-UC. We believe that PALI-2108’s targeted activation and localized delivery in both the ileum and colon are particularly relevant to Crohn’s disease, which can affect multiple regions of the gastrointestinal tract. We are finalizing the design of the Phase 2 ASCENTRA-CD trial and expect to submit an IND in the second half of 2026. With active programs in both Crohn’s disease and ulcerative colitis, PALI-2108 is positioned to address the two largest indications within IBD.” Summary of Financial Results Research and development expenses were $7.4 million for the three months ended June 30, 2026, compared to $1.7 million for the three months ended June 30, 2025. The increase was primarily attributable to higher research and development employee-related expenses, including increased non-cash stock-based compensation expense, and higher PALI-2108 program expenses driven by increased clinical operation expenses, increased chemistry, manufacturing and controls (CMC) activities and expanded preclinical and translational science efforts supporting advancement of PALI-2108 into Phase 2 development. General and administrative expenses were $4.8 million for the three months ended June 30, 2026, compared to $1.2 million for the three months ended June 30, 2025. The increase was primarily attributable to higher employee-related expenses, including increased non-cash stock-based compensation expense, as well as higher professional fees supporting the Company's continued growth and clinical advancement. The Company recognized license revenue of $0.5 million for the three months ended June 30, 2026 related to the achievement of a milestone pursuant the co-development and distribution agreement with Newsoara, a joint venture established by Biolead Medical Technology Limited. No license revenue was recognized for the three months ended June 30, 2025. Net loss was $10.6 million, or a net loss of $0.05 per share, for the three months ended June 30, 2026, compared to a net loss of $2.8 million, or a net loss of $0.58 per share, for the three months ended June 30, 2025. As of June 30, 2026, the Company had $125.2 million in cash and cash equivalents and believes its existing cash resources are sufficient to fund operations through major clinical development milestones, including the anticipated primary efficacy readout from the Phase 2 ASCENTRA-UC trial expected in the second half of 2027 and the planned primary efficacy readout from the Phase 2 ASCENTRA-CD trial expected in early 2028. About Palisade Bio Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company developing prodrugs for patients living with inflammatory and fibrotic diseases. The Company’s lead clinical product candidate, PALI-2108, is being advanced into Phase 2 clinical trials as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Despite the availability of multiple biologic and small-molecule therapies, many patients with UC and CD do not achieve durable remission, lose response over time, or discontinue treatment because of safety or tolerability limitations. The Company believes PALI-2108 has the potential to address these limitations through once-daily oral dosing, targeted lower-intestinal bioactivation and broad PDE4-mediated anti-inflammatory activity. Palisade Bio is now advancing into Phase 2 development for UC and CD. For more information, please go to www.palisadebio.com. Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PALI-2108, dosing levels and timing of key PALI-2108 development milestones such as regulatory submissions and approvals, trial enrollments and commencements and efficacy readouts, and the Company's expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. Investor Relations Contact JTC Team, LLCJenene [email protected] Palisade Bio, Inc.Condensed Consolidated Balance Sheets (Unaudited)(in thousands, except share and per share amounts) Palisade Bio, Inc.Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts) Palisade Bio, Inc.Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to support execution through key clinical readouts Denver, CO, May 12, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations. Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn’s disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications. The data demonstrated sustained exposure of the active metabolite above IC90 thresholds, along with favorable distribution to colon tissue, supporting consistent target engagement at the site of disease. In addition, pharmacodynamic findings showed modulation of key inflammatory and fibrotic pathways, reinforcing the potential of PALI-2108 to address both components of IBD. The program continues to demonstrate a favorable safety and tolerability profile, reinforcing confidence in the potential of PALI-2108 as it advances into Phase 2 development. “We continue to see a consistent and differentiated profile emerging for PALI-2108 across IBD,” said JD Finley, Chief Executive Officer of Palisade Bio. “The totality of data generated to date supports our decision to advance into Phase 2 development in both ulcerative colitis and Crohn’s disease. With consistent target engagement, evidence of activity across key inflammatory and fibrotic pathways, and a favorable safety profile, we are increasingly confident in the potential of PALI-2108 as we move into development this year.” Recent Highlights and Anticipated Milestones Completed Phase 1a/b for PALI-2108, Reported Positive Data Favorable safety and tolerability profile Evidence of target engagement in ileal and colon tissue Early signals of clinical activity in Crohn’s disease Advancing Toward Phase 2 IND submission for Phase 2 UC trial expected in 2Q 2026 IND submission for Phase 2 CD trial expected in 2H 2026 Phase 2 UC trial initiation targeted for Q3 2026 Phase 2 CD trial initiation targeted for Q1 2027 Well-Capitalized Through Potential Key Value Inflection Points Phase 2 UC readout (expected in 2H 2027) Phase 2 CD readout (expected early 2028) PALI-2108 is an orally administered, once-daily PDE4 inhibitor prodrug designed for targeted activation in the ileum and colon. Its localized bioactivation is intended to enable sustained target inhibition at the site of inflammation while minimizing systemic exposure and improving tolerability. Summary of Financial Results Research and development expenses were $6.4 million for the three months ended March 31, 2026, compared to $1.0 million for the three months ended March 31, 2025. The increase of $5.4 million was primarily attributable to (i) an increase in research and development employee-related expenses, including increased non-cash share-based compensation expense, (ii) a net increase in clinical trial-related expenses associated with the ongoing clinical trials of PALI-2108, and (iii) an increase in chemistry, manufacturing and controls (“CMC”) expenses. General and administrative expenses were $4.4 million for the three months ended March 31, 2026, compared to $1.4 million for the three months ended March 31, 2025. The increase of $3.0 million was primarily attributable to higher employee-related expenses, including increased non-cash share-based compensation expense, as well as higher professional fees. As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 CD that is expected in early 2028. About Palisade Bio Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD). Palisade Bio is now advancing towards Phase 2 clinical studies in UC and Crohn’s disease. For more information, please go to www.palisadebio.com. Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: the potential mechanisms of action and therapeutic benefits of PALI-2108, plans for and timing of regulatory submissions and approvals, clinical trials and efficacy readouts and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 [email protected] Palisade Bio, Inc. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) Palisade Bio, Inc. Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except share and per share amounts) Palisade Bio, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)

VANCOUVER, BC, Aug. 28, 2025 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") is pleased to announce that at its meeting ("Meeting") of shareholders (the "Shareholders") held yesterday Shareholders approved the re-election of Gregor Gregersen and Elizabeth Harrison to the Board of Directors of the Company (the "Board"). In addition, Collin Kettell and Philip O'Neill were elected to the Board. Former director and Chief Financial Officer Bassam Moubarak did not stand for re-election. Effective immediately, Mr. O'Neill will also serve as the Company's Chief Operating Officer. Also during the Meeting, Shareholders approved the proposed return of capital transaction (the "Transaction") as announced in the news release dated July 24, 2025. The Transaction remains subject to receipt of the final order (the "Final Order") by the British Columbia Supreme Court (the "Court"), approval of the TSX Venture Exchange ("TSXV"), and completion of required regulatory filings. The Company will announce the effective date of the Transaction once all necessary approvals have been obtained. All other matters put forward before the Shareholders at the meeting for consideration and approval, including the re-appointment of Deloitte LLP, Chartered Professional Accountants, as auditor of the Company at a remuneration to be fixed by the Board, renewal of the stock option plan of the Company, the grant of conditional stock options under the Company's stock option plan, as well as the potential creation of Michael Parker as a new Control Person, as such term is defined in the polices of the TSXV, of the Company, all as set out in the Company's Management Information Circular dated July 21, 2025, were approved. Philip O'Neill Mr. O'Neill is an experienced mining executive and corporate director. He is currently the President and founder of MP1 Capital, a Calgary based investment company created to focus on the natural resources sector. Mr. O'Neill was Director and Chief Operating Officer of Palisades Goldcorp Ltd. from 2019 to 2021, during which Palisades Goldcorp Ltd. became one of the most active financiers in the junior mining space. In 2010, Mr. O'Neill founded TSX listed Sunward Resources Ltd. ("Sunward") where he held the positions of CEO and Director, raising $81 million in a 10-month span to advance the Titiribi gold/copper project in Colombia. In 2015, Mr. O'Neill negotiated Sunward's acquisition by NovaCopper Inc., now Trilogy Metals Inc., at a +140% premium to market. Mr. O'Neill has also held directorship roles for several TSX, TSX Venture, and ASX listed companies. About Palisades Goldcorp Ltd. Palisades Goldcorp Ltd. is a Canadian company incorporated in the province of British Columbia acting primarily a resource investment company and merchant bank focused on junior companies in the resource and mining sector. The Company seeks to acquire equity participation in pre-initial public offering and early-stage public resource companies with undeveloped or undervalued high quality projects. The Company focuses on companies that are in need of financial resources to realize their full potential, are undervalued in capital markets, and/or operate in jurisdictions with low to moderate local political risk. The Company is focused on providing retail and institutional investors with exposure in the junior resource space. The Company primarily expects to continue to make investments, pursuant to its dual investment strategy, to achieve broad sector exposure with upside in the event of appreciation in mineral commodities prices, while also providing the potential to realize appreciation in net asset values as a result of discoveries by issuers in which the Company holds larger positions. At present, and after the acquisition of Palisades Investments Ltd (formerly Radio Fuels Energy Corp.) in February 2025, Palisades has a portfolio of equity investments, or securities convertible into equity investments, in over 125 junior resource issuers. Through subsidiaries, Palisades holds exploration properties in Nevada and a uranium exploration property in Canada. The Company owns 100% of Made in America Gold Corp., which ranks as the largest junior mineral claim holder in the State of Nevada, as well as 100% of Radio Fuels Resources Corp., which owns the Eco Ridge Uranium Project in Elliot Lake, Ontario. The common shares of the Company are listed and posted for trading on the TSXV under the symbol "PALI". Palisades' management team identifies highly prospective assets in politically safe jurisdictions and seeks to unlock their value by providing strategic investments, proven technical skills, global knowledge, and increased access to industry relationships. Notice of Hearing The application for the Final Order approving the Arrangement is currently scheduled for September 8, 2025, at 9:45 a.m. (Pacific Daylight Time), or as soon thereafter as counsel may be heard, at the Courthouse, 800 Smithe Street, Vancouver, British Columbia, or at any other date and time as the Court may direct. Any Shareholder or any other interested party who wishes to appear or be represented and to present evidence or arguments at that hearing must file and serve a response to petition by no later than 5:00 p.m. (Pacific Daylight Time) on September 2, 2025, along with any other documents required, all as set out in the (i) Interim Order included in the Information Circular and available on the Company's SEDAR+ profile at www.sedarplus.ca, and (ii) Notice of Hearing of Petition attached as Schedule "A". If a Shareholder or other interested party wishes to appear or be represented and to present evidence or argument at the hearing and they file and serve a response to petition after September 2, 2025, at the hearing for the final order counsel for the Company will seek leave from the court to permit the late-filing party to be heard. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this release. Cautionary Statements Regarding Forward Looking Information This news release contains certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operations and activities of Palisades, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or" should" occur or be achieved. All statements in this news release, other than statements of historical fact, including, without limitation, statements relating to the successful completion of the Transaction, receipt of the Final Order by the Court, TSXV approval and any tax effects thereof, and the plans and business of Palisades are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by Palisades, are inherently subject to significant business, economic, technical, geologic, environmental, regulatory, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these items. Palisades does not assume any obligation to update forward-looking statements should beliefs, opinions, projections, or other factors, change, except as required by applicable securities laws. SCHEDULE "A" No. Vancouver Registry IN THE SUPREME COURT OF BRITISH COLUMBIA IN THE MATTER OF SECTION 288 OF THE BUSINESS CORPORATIONS ACT, SBC 2002, CHAPTER 57 AS AMENDED AND IN THE MATTER OF A PROPOSED ARRANGEMENT INVOLVING PALISADES GOLDCORP LTD. AND ITS SHAREHOLDERS PALISADES GOLDCORP LTD. PETITIONER NOTICE OF HEARING OF PETITION (FOR FINAL ORDER) TO: Shareholders, Securityholders, Directors and Auditor of Palisades Goldcorp Ltd. TAKE NOTICE that a petition by the Petitioner herein, Palisades Goldcorp Ltd., will be heard at the courthouse at 800 Smithe Street, Vancouver, BC V6Z 2E1 on September 8, 2025 at 9:45 a.m. This matter is not an application for judicial review Date of hearing The petition is unopposed, by consent or without notice. Duration of hearing It has been agreed by the parties that the hearing will take 15 minutes. Jurisdiction This matter is not within the jurisdiction of an associate judge. NOTICE IS HEREBY GIVEN that a petition will be made by the Petitioner, Palisades Goldcorp Ltd. ‎‎("Palisades") to the presiding judge in the Supreme Court of British Columbia ‎‎(the "Court") at the courthouse at 800 Smithe Street, Vancouver, BC, V6Z 2E1 on Monday, September 8, 2025 at 9:45 a.m. ‎for an order (the "Final Order") approving a plan of arrangement (the ‎‎"Plan of Arrangement"), or at such other date and time as the Court may direct (the "Petition"), pursuant to the Business Corporations Act, S.B.C., 2002, c. 57, as ‎amended (the "BCBCA").‎ AND NOTICE IS FURTHER GIVEN that by Interim Order of the Court, pronounced July 23, 2025, the ‎Court has given directions as to the calling of a meeting (the "Special Meeting") of the shareholders of Palisades, for the purpose of, inter alia, considering, voting upon and approving the Plan of ‎Arrangement. AND NOTICE IS FURTHER GIVEN that the Court has been advised that, if granted, the Final Order approving the Plan of Arrangement and the declaration that the Plan of Arrangement is substantively and procedurally fair and reasonable to the Palisades Shareholders who will receive securities of New Found Gold Corp, on a pro rata basis, in connection with the Plan of Arrangement, will serve as a basis of a claim for the exemption from the registration requirements of the United States Securities Act of 1933, as amended, set forth in Section 3(a)(10) thereof with respect to the issuance and exchange of such securities under the proposed Plan of Arrangement. IF YOU WISH TO BE HEARD, any person affected by the Final Order sought may appear (either in person or by counsel) and make submissions at the hearing of the Final Order if such person has filed with the Court at the Court Registry, 800 Smithe Street, Vancouver, British Columbia, a Response to Petition ("Response") pursuant to Rule 16-1(4) of, and in the form prescribed by, the Supreme Court Civil Rules and delivered a copy of the filed Response, together with all material on which such person intends to rely at the hearing of the Petition, including an outline of such person's proposed submissions, to Palisades at its address for delivery set out below by or before 12:00 p.m. (Vancouver time) on Tuesday, September 2, 2025. Palisades' address for delivery is: DLA Piper (Canada) LLP Suite 2700 – 1133 Melville Street, Vancouver, B.C. V6E 4E5 Attention: Parker Fogler Fax number: (604) 687-1612 Email address: [email protected] IF YOU WISH TO BE NOTIFIED OF ANY ADJOURNMENT OF THE PETITION, YOU MUST GIVE NOTICE OF YOUR INTENTION by filing and delivering the form of "Response" as aforesaid. You may obtain a form of Response at the Court Registry, 800 Smithe Street, Vancouver, British Columbia, V6Z 2E1. AT THE HEARING OF THE PETITION the Court may approve the Plan of Arrangement as presented, or may approve it subject to such terms and conditions as the Court deems fit. IF YOU DO NOT FILE A RESPONSE and attend either in person or by counsel at the time of such hearing, the Court may approve the Plan of Arrangement, as presented, or may approve it subject to such terms and conditions as the Court shall deem fit, all without any further notice to you. If the Plan of Arrangement is approved, it will significantly affect the rights of the holders of securities of Palisades or rights to acquire securities of Palisades. A copy of the Petition filed herein, Notice of Petition (for Final Order) and other documents in the proceeding will be furnished to any Shareholder upon request in writing addressed to the solicitors of Palisades at its address for delivery set out above. No. Vancouver Registry IN THE SUPREME COURT OF BRITISH COLUMBIA IN THE MATTER OF SECTION 288 OF THE BUSINESS CORPORATIONS ACT, SBC 2002, CHAPTER 57 AS AMENDED AND IN THE MATTER OF A PROPOSED ARRANGEMENT INVOLVING PALISADES GOLDCORP LTD. AND ITS SHAREHOLDERS PALISADES GOLDCORP LTD. PETITIONER NOTICE OF HEARING OF PETITION (FOR FINAL ORDER) DLA Piper (Canada) LLP Barristers & Solicitors Suite 2700 ‎ ‎1133 Melville Street Vancouver, BC V6E 4E5‎ Tel. No. 604.687.9444 Fax No. 604.687.1612 File No.: 117984-00002 TJU/jid SOURCE Palisades Goldcorp Ltd. View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2025/28/c2003.html

Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Access here Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced positive topline results from its completed Phase 1 studies of PALI-2108, a novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC). Additionally, the Company announced the release of a Virtual Investor “What This Means” segment to discuss the topline data, which is now available here. The Phase 1 program, which included single ascending dose (SAD), multiple ascending dose (MAD), and cross-over food effect (FE) studies in adult healthy volunteers, as well as a small cohort of UC patients, successfully met its primary endpoints of safety, tolerability, and pharmacokinetics (PK). The data support progression into Phase 2 development. “These data validate PALI-2108’s targeted prodrug design and provide compelling evidence that the drug reaches therapeutic concentrations in the colon with lower systemic exposure,” said Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio. “The observed tissue penetration of the active drug and the absence of serious adverse events, together with our significant body of nonclinical PK data, support our confidence in advancing PALI-2108 into patient-focused trials for fibrostenotic Crohn’s disease and ulcerative colitis.” Key Phase 1 Findings Safety & Tolerability: No serious adverse events (SAEs) or laboratory/EKG-related adverse events were observed across SAD, MAD and FE cohorts. In the SAD study (15–450 mg), only mild and reversible treatment-emergent AEs (TEAEs) occurred, limited to the highest dose (450 mg). MAD cohorts (15, 30, and 50 mg BID over 7 days, as well as 30 mg titrated over 7 days) showed mostly minor TEAEs and most often at higher doses, with a moderate event at 50 mg BID leading to withdrawal. Importantly the 15 mg BID dose was free of any TEAEs and the 30mg BID titrated dose had one minor TEAE that resolved within the first days of the study. Pharmacokinetics: PK analysis confirmed the delayed-release, terminal ileum-targeted and colon-targeted profile of PALI-2108. Plasma and tissue PK demonstrated that therapeutically relevant concentrations (above estimated IC₅₀) were achieved in colon tissue up to 24 hours post-dose. Plasma-to-tissue ratios confirmed localized drug activation in the distal gut with low systemic exposure. Cmax and AUC increased roughly proportionally with dose; food intake modestly delayed Tmax and modestly reduced Cmax, consistent with the prodrug’s intended release profile. Modeling and Dosing: Population PK modeling and dose-exposure simulations support a therapeutic window aligned with the safety and tolerability observed in Phase 1. The data support continued dose exploration in future clinical trials. “The pharmacokinetic and safety data are highly encouraging, particularly the tissue exposure levels in colon biopsies,” added Dr. Gaetano Morelli, Principal Investigator of the Phase 1 study and clinical gastroenterologist. “This targeted approach could address a critical gap in treatment for patients with fibrostenotic disease and could reduce risks associated with systemic PDE4 inhibition.” Based on these results, Palisade Bio plans to initiate an additional safety and tolerability and PK/PD exploration Phase 1b cohort in FSCD while completing longer-term chronic safety and toxicology studies, to be followed closely by initiating Phase 2 clinical programs to assess PALI-2108’s efficacy, safety, and tolerability in patients with FSCD as well as those with moderate to severe UC. The planned Phase 1b cohort is expected to evaluate multiple dosing strategies to define optimal therapeutic exposure and patient response and the planned Phase 2 studies are expected to evaluate clinically meaningful endpoints for the patients with FSCD and UC. For more information about the Phase 1a/b clinical study, visit clinicaltrials.gov and reference identifier NCT06663605. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Forward Looking Statements Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s Phase 1b/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b/2a clinical study. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 [email protected]